The AGENT study (Phase III)

The AGENT study (Phase III)

Isofol is developing the drug candidate arfolitixorin, which is currently being evaluated in first-line treatment for advanced/metastatic colorectal cancer* (mCRC) in the pivotal, global Phase III AGENT study. The study is being conducted in the United States, Canada, Europe, Australia and Japan.

 

 

 

* Colorectal cancer, also known as intestinal or rectal cancer, is a form of cancer that arises from uncontrolled cell growth in the large intestine, rectum or appendix.